Jasper Therapeutics Inc. (JSPR)
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
📈 **POSITIVE** • High confidence analysis (82%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (87%) **Content type:** Clinical